Search Results

BiondVax Pharmaceuticals Ltd. announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550 and provided it an extension until October 30, 2023, to demonstrate compliance.

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, is pleased to announce a change of its corporate name to Scinai Immunotherapeutics Ltd.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.

BiondVax Pharmaceuticals Ltd. announced that Mr. Amir Reichman, BiondVax’s CEO will present at the Biotech Showcase conference being held Jan. 9-11, 2023.

BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) today published its financial results for the first quarter ended March 31, 2023, and provided a business update.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland.

BiondVax Pharmaceuticals Ltd. today announced that Professor Dr. med. Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).

BiondVax Pharmaceuticals Ltd. published its full-year financial results for the year ended December 31, 2022, and provided a business update.

BiondVax Pharmaceuticals Ltd. today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.

BiondVax Pharmaceuticals Ltd. announces today the receipt of formal notifications from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity and minimum bid price.